Should We Reconstruct Coronal Plane Fractures in Multifragmentary Pertrochanteric Fractures? A Randomized Controlled Trial.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 42389460.
- Also identified by DOI 10.2106/JBJS.OA.26.00148 and PMC identifier 13322473.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Coronal plane fractures are increasingly identified in multifragmentary pertrochanteric (AO Foundation/Orthopaedic Trauma Association [AO/OTA] 31-A2) fractures, yet their clinical significance is under-researched. The aim of this study was to evaluate whether wire augmentation during Proximal Femur Nail Antirotation Asia (PFNA-II) fixation improves functional outcomes-regain of abductor strength and modified Harris Hip Score (mHHS)-compared with PFNA-II alone at 18-month follow-up. The secondary outcomes such as time to union, pain scores (Visual Analog Scale [VAS]), and complications were also assessed. In this single-center, randomized controlled trial, 142 patients of Asian race and Indian ethnicity aged older than 60 years with AO-OTA 31-A2 fractures were treated using PFNAII, with or without wire augmentation for coronal fragments. Preoperative computed tomography (CT) assessed coronal fragment size. Among them, 116 patients who completed 18-month follow-up were analyzed. Modified intention-to-treat analysis was performed. At 18 months, augmentation produced greater abductor strength (Δ 8.21%, 95% confidence interval, 4.4-12.83; p < 0.001) with no significant difference in mHHS (Δ 3.31 points, -1.3-7.9; p = 0.16). In fragments >50%, wire augmentation led to a clinically relevant 10% strength gain, exceeding the minimal clinically important difference (MCID) of 8.2%. However, VAS was similar between groups. Controls showed more varus collapse, likely due to a persisting posteromedial void when the fragment is not stabilized. Wire augmentation improved abductor strength recovery, especially when fragment size exceeded 50%, supporting its use in such cases. However, mHHS were similar between the groups. Level I Therapeutic. See Instructions for Authors for a complete description of levels of evidence.